Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Trial Profile

Safety and efficacy of idelalisib in patient with chronic lymphocytic leukemia or lymphoma relapsing after allogeneic hematopoietic cell transplantation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 As of June 22, 2017, a total of 28 patients had been registered according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Dec 2017 New trial record
    • 12 Dec 2017 Results (n=24) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top